Oligodendrocyte-Like Cell Induction Using OLIG2 S147 Mutant and SOX10
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for differentiating human pluripotent stem cells into oligodendrocyte-like cells suffer from inefficiency and often result in the induction of astrocyte-like cells or motor nerve cells, with significant variation in differentiation efficiency among cell lines.
Innovation Solution
A method involving the increased abundance of an OLIG2 mutant lacking a serine residue at position 147 or substituted with another amino acid, combined with SOX10, is introduced into human pluripotent stem cells using vectors regulated by a tetracycline response element, allowing controlled expression through antibiotics, to efficiently produce oligodendrocyte-like cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If human pluripotent stem cells are induced to differentiate into oligodendrocyte-like cells by expressing SOX10 gene, then oligodendrocyte-like cells are produced, but differentiation induction efficiency varies significantly between cell lines and astrocyte-like cells are also induced
Solution Approach 1:
The invention changes the molecular parameters by using a specific mutant form of OLIG2 (lacking serine at position 147) instead of wild-type OLIG2, and combines it with SOX10 expression. This parameter change in the transcription factor composition enables efficient and specific differentiation into oligodendrocyte-like cells while suppressing astrocyte formation, resolving both the efficiency and purity issues.
Solution Approach 2:
The invention uses a composite approach by combining two transcription factors (OLIG2 mutant and SOX10) to achieve superior differentiation control. This composite strategy of co-expressing multiple transcription factors synergistically directs stem cell differentiation toward oligodendrocyte lineage with high efficiency and specificity, avoiding the limitations of single-factor approaches.
2Productivity
If human pluripotent stem cells are induced to differentiate into oligodendrocyte-like cells by expressing OLIG2, then oligodendrocyte-like cells are produced, but motor nerve cells are also induced
Solution Approach 1:
The invention modifies the OLIG2 protein parameter by removing the serine residue at position 147, creating a mutant form with altered functionality. This parameter change in the OLIG2 transcription factor enables selective differentiation into oligodendrocyte-like cells while preventing differentiation into motor nerve cells, thereby improving both efficiency and specificity.
Solution Approach 2:
The invention applies local quality by making a specific localized change to the OLIG2 protein structure (removing serine at position 147). This localized modification alters the transcription factor's function in a specific way that directs differentiation toward oligodendrocyte lineage while suppressing other lineages, achieving precise cell type control.
Data Source
AI summary
A method is provided for producing oligodendrocyte-like cells, including (A) increasing abundances of oligodendrocyte transcription factor 2 (OLIG2) mutant and SRY-box transcription factor 10 (SOX10) in human pluripotent stein cells and (B) culturing the human pluripotent stem cells in which the abundances of the OLIG2 mutant and the SOX10 are increased and consequently differentiating the human pluripotent stem cells into oligodendrocyte-like cells, in which the OLIG2 mutant lacks a serine residue of wild-type OLIG2 at position 147, or the serine residue of the wild-type OLIG2 at position 147 is substituted with an amino acid other than serine.